NuCana (NCNA) Return on Capital Employed (2018 - 2025)
NuCana (NCNA) reported Return on Capital Employed of 68.47% for Q4 2025, up 19453.0% on a YoY basis from N/an in Q4 2024, and up 23.19% sequentially from 89.13% in Q3 2025.
NuCana (NCNA) Return on Capital Employed (2018 - 2025) Analysis & Trends
NuCana (NCNA) has 8 years of Return on Capital Employed data on file, last reported at 68.47% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 19453.0% year-over-year to 68.47%; the trailing twelve-month figure through Dec 2025 stood at 68.47% (up 19453.0% YoY), and the FY2025 full-year result was 116.34%, up 6983.0% from the prior year.
- Return on Capital Employed grew to 68.47% in Q4 2025, from 89.13% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 43.6% in Q1 2021 to a low of 672.27% in Q3 2024.
- A 5-year average of 184.79% and a median of 98.15% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 51823 bps in 2024 and jumped 58314 bps in 2025, its largest moves.
- Tracing NCNA's Return on Capital Employed over 5 years: stood at 66.9% in 2021, then plunged by 38 bps to 92.63% in 2022, then slumped by 91 bps to 176.79% in 2023, then slumped by 49 bps to 263.0% in 2024, then soared by 74 bps to 68.47% in 2025.
- Business Quant data shows NCNA's Return on Capital Employed at 68.47% in Q4 2025, 89.13% in Q3 2025, and 420.12% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | NuCana | 14.60 Bn | 14.60 Bn | - | -68.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -68.47% |
| Sep 30, 2025 | -89.13% |
| Jun 30, 2025 | -420.12% |
| Mar 31, 2025 | -291.42% |
| Dec 31, 2024 | -263.00% |
| Sep 30, 2024 | -672.27% |
| Jun 30, 2024 | -526.42% |
| Mar 31, 2024 | -273.36% |
| Dec 31, 2023 | -176.79% |
| Sep 30, 2023 | -154.04% |
| Jun 30, 2023 | -120.77% |
| Mar 31, 2023 | -103.68% |
| Dec 31, 2022 | -92.63% |
| Sep 30, 2022 | -76.52% |
| Jun 30, 2022 | -72.43% |
| Mar 31, 2022 | -76.76% |
| Dec 31, 2021 | -66.90% |
| Sep 30, 2021 | -57.41% |
| Jun 30, 2021 | -50.10% |
| Mar 31, 2021 | -43.60% |